The Company's focus on Human Care in the Indian market is proving to be successful. Our unique TSE technology aligns seamlessly with the healthcare landscape in
While head and neck cancer pose a significant global challenge,
In
In our role as a technology partner for the university hospital's innovation centre, ChemoTech has already implemented the initial IQwave(TM) system ahead of the official study commencement. This pre-installation was conducted to train the team in TSE treatment techniques. The hospital is currently in the process of compiling a case study report detailing the outcomes of the initial treatments.
As per the official study protocol, 9 out of the total 30 patients have undergone treatment. The investigators have submitted a request to modify the inclusion criteria, advocating for the incorporation of TSE at an earlier stage. If approved, this modification would significantly expand the pool of eligible patients. Consequently, doctors would be empowered to administer TSE treatment with curative intent, particularly for cases where the tumour recurs post-surgical intervention. There is optimism that the ethics committee, in its upcoming meeting, will approve the revised protocol. This approval would mark the biggest milestone toward achieving our goal of establishing TSE as a curative treatment method, thereby enhancing the Company's global potential.
The intention is to commence treatment for the initial patients under the revised protocol in the first or second quarter of 2024.
Here are some remarks from Dr.
"I am filled with optimism that the approval of the amended protocol will mark the beginning of a groundbreaking era, allowing TSE to unfold it´s true potential in curative therapies--a crucial advancement addressing a major clinical need. This pioneering approach, both biologically and scientifically plausible, signifies a historic milestone, as neither ablation nor electroporation technologies have been previously considered in trials of earlier lines of therapy for Head and Neck tumours."
"The fact that our TSE therapy is currently being evaluated for its curative potential in a clinical trial at one of the leading University hospitals in
For further information please contact:
Phone: +46 (0)10-218 93 00
E-mail: ir@chemotech.se
ChemoTech is a Swedish medical technology company based in
[1] https://fhno.org/blog/Head-And-Neck-Cancers-in-India)
https://news.cision.com/chemotech/r/scandinavian-chemotech-updates-on-its-most-important-milestone,c3884938
https://mb.cision.com/Main/14967/3884938/2462675.pdf
https://news.cision.com/chemotech/i/update,c3244267
(c) 2023 Cision. All rights reserved., source